The brokerage announced plans to raise capital for “general corporate purchases” by issuing convertible notes — debt that ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase ...

“This agreement reflects growing demand for continuous Earth observation,” said Jeff Kerridge, SVP of Global Sales at Satellogic. “We’re able to support persistent, high-revisit coverage across ...

Compass, Inc. (NYSE: COMP) (the "Company"), today announced the pricing of its offering of $850.0 million in aggregate principal amount of convertible senior notes due 2031 (the "Notes") in a private ...

On Jan. 7, 2026, investors weighed a massive notes deal, raised guidance, and an approved merger reshaping this real estate ...

FuboTV Inc. (NYSE: FUBO) today announced that no holders of Fubo's Convertible Senior Secured Notes due 2029 tendered their notes for repurchase.

Compass, Inc. (NYSE: COMP) (the "Company") announces that it intends to offer (the "Offering"), subject to market and other conditions, $750.0 million in aggregate principal amount of convertible ...

(NASDAQ: EVRG) (“Evergy”) today announced that it has entered into separate, privately negotiated repurchase agreements with certain holders of its 4.50% Convertible Notes due 2027 (the “Notes”) to ...

Catenai on Monday said that under the terms of the new extension agreement, Klarian will repay the GBP624,250 now due under the CLN and related fees by March 31.

Summary • Profusa, Inc. shares fell 18.2% to $0.0996 during intraday trading.• The company announced a restructuring of Senior Secured Convertible Notes to enhance repayment flexibility and reduce ...

- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a ...